Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB35 + Lenalidomide vs Rituximab + Lenalidomide in R/R Follicular Lymphoma
NCT07562022Phase 3Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2026
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SCTB35 in follicular lymphoma (FL) (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoints: Adverse Events at 3 years and Progression-Free Survival at 3 years. Started Jun 2026; status: recruiting.
02
Drugs
SCTB35
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07562022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562022.